WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 205525
Description: LY2780301 is an orally bioavailable inhibitor of the serine/threonine protein kinase Akt (protein kinase B) with potential antineoplastic activity. Akt inhibitor LY2780301 binds to and inhibits the activity of Akt, which may result in inhibition of the PI3K/Akt signaling pathway, thereby leading to inhibition of cell proliferation and the induction of apoptosis in tumor cells. Activation of the PI3K/Akt signaling pathway is frequently associated with tumorigenesis and dysregulated PI3K/Akt signaling may contribute to tumor resistance to a variety of antineoplastic agents.
MedKoo Cat#: 205525
Synonym: LY2780301; LY-2780301; LY 2780301
IUPAC/Chemical Name: NONE
1: Azaro A, Rodon J, Calles A, Braña I, Hidalgo M, Lopez-Casas PP, Munoz M,
Westwood P, Miller J, Moser BA, Ohnmacht U, Bumgardner W, Benhadji KA, Calvo E. A
first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt
Inhibitor, in patients with advanced or metastatic cancer. Invest New Drugs. 2015
Jun;33(3):710-9. doi: 10.1007/s10637-015-0241-7. Epub 2015 Apr 24. PubMed PMID:
(Last updated: 4/21/2016).